Attached files
file | filename |
---|---|
EX-99.1 - WINDTREE THERAPEUTICS INC /DE/ | v207971_ex99-1.htm |
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
___________________________
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
January
11, 2011
Date of
Report (Date of earliest event reported)
Discovery
Laboratories, Inc.
(Exact
name of registrant as specified in its charter)
Delaware
|
000-26422
|
94-3171943
|
(State
or other jurisdiction
of
incorporation)
|
(Commission
File Number)
|
(IRS
Employer
Identification
Number)
|
2600
Kelly Road, Suite 100
Warrington,
Pennsylvania 18976
(Address
of principal executive offices)
(215)
488-9300
(Registrant's
telephone number, including area code)
(Former
name or former address, if changed since last report)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
o
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
o
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
o
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
o
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
Item
8.01.
|
Other
Events.
|
On
January 12, 2011, Discovery Laboratories, Inc. (the “Company”) issued a press
release announcing that, on January 11, 2011, a NASDAQ Listing Qualifications
Panel (the “Panel”) determined that the Company has regained compliance with
Nasdaq Listing Rule 5550(a)(2) (the Minimum Bid Price Rule) and that the Company
is in compliance with all other listing standards for continued listing on The
NASDAQ Capital Market®. Accordingly,
the Company’s common stock will continue to be listed on The NASDAQ Capital
Market. The press release is attached as Exhibit 99.1.
Item
9.01.
|
Financial Statements
and Exhibits.
|
|
(d)
|
Exhibits
|
|
99.1
|
Press
Release dated January 12, 2011.
|
2
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
Discovery Laboratories, Inc. | |||
|
By:
|
/s/ W. Thomas Amick | |
Name: | W. Thomas Amick | ||
Title: | Chairman of the Board and | ||
Chief Executive Officer |
Date: January
12, 2011
3